Consequently, molecular profiling of individual cancers, including sequencing of TP53 to determine mutation status and detection of endogenous levels of both FLp53 and ∆40p53, is necessary prior to altering ∆40p53 levels, if it was to be used as a targeted therapy in cancer or aging related diseases. This evidence concerns the gene TP53 and cancer.